依达拉奉联合丁苯酞对进展性卒中治疗的临床研究

Clinical Observation of Edaravone Combination of Butylphthalide in Treatment of Advancing Stroke

目的:评价依达拉奉联合丁苯酞治疗进展性卒中的临床疗效。方法:选择发病在72h内的进展性卒中患者120例,随机分成治疗组60例和对照组60例。对照组给予改善微循环、降颅压等对症治疗,并且在此基础上给予丁苯肽0.2g,3次/d,疗程14d;治疗组则在常规治疗基础上给予依达拉奉30mg加入生理盐水100mL静脉滴注,每日2次,连用14d,丁苯肽0.2g,3次/d,疗程14d。将两组病例进行NIHSS评分及BI评分。结果:治疗组与对照组NIHSS评分和BI评分在治疗后14d、1个月均有统计学差异(P<0.05)。结论:应用依达拉奉联合丁苯酞优于仅丁苯酞治疗进展性卒中的疗效。

Objective ： To evaluate the effect of combination of butylphthalide in the treatment of the acute advancing stroke. Method： The incidence of advancing stroke in 72h patients with 120 patients, randomly divided into 60 patients with treatment group and control group with 60 patients. The control group with conventional therapy, namely in the given improve microcirculation, and intracranial pressure regulating blood pressure and blood glucose and other symptomatic treatment given based on SBR peptide 0.2g, daily 3, course of treatment is 14 days ; the treatment group on the basis of routine treatment of edaravone 30mg joined 100mL saline infusion, 2 times daily, with 14 days, Butylphthalide 0.2g for 3 times a day, 14 days in a course. Two cases of the United States of America NIH Stroke Scale （NIHSS ） score and ability of daily living （ BI ） score. Result：Treatment group and control group in the NIHSS score and BI score in the 14 days after treatment, 1 month are statistical differences （ P 〈 0.05）. Conclusion：The application effect of edaravone combined butylphthalide is better than that of butylphthalide treating progressing stroke.